Biotech Analyst Goonewardene, along with head and neck key opinion leader Dr. Perez (Sarah Cannon) (relevant companies MRUS BCAX EXEL) participate in an Analyst/Industry conference call to be held on April 21 at 11 am. Webcast Link
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus’s Promising Position in Healthcare: Buy Rating Backed by Pivotal Studies and Upcoming Data Milestones
- Promising Outlook for Merus: Buy Rating Backed by Strong Clinical Trial Potential and Financial Stability
- Buy Rating on Merus: Promising Potential of Petosemtamab in Combination with PD-1 Therapy for Head and Neck Cancer
- Merus price target lowered to $70 from $73 at BofA
- Merus N.V. Reports 2024 Earnings and Clinical Progress